摘要
目的探讨分子靶向单抗类药物治疗晚期非小细胞肺癌CA125、EGFR水平影响变化。方法 60例晚期非小细胞癌患者按照治疗方法不同分为对照组和研究组(各组30例)。对照组行常规化疗治疗,研究组则在化疗基础之上行分子靶向单抗类药物治疗。对比分析两组患者的临床治疗效果及非小细胞肺癌的CA125、EGFR、CEA表达水平及不良反应发生率。结果经研究发现研究组和对照组临床有效率分别为56. 67%和26. 67%,两组差异具有统计学意义(P <0. 05);治疗后研究组和对照组的CA125分别为(421. 5±73. 8)(521. 6±105. 1),EGFR分别为(40. 5±10. 2)(58. 1±13. 5),CEA分别为(3. 2±1. 3)(4. 2±0. 8),两组差异均具有统计学意义(P <0. 05);研究组和对照组的治疗不良反应发生率分别为16. 67%和20. 00%,两组差异不具有统计学意义(P> 0. 05)。结论通过对晚期非小细胞肺癌患者行分子靶向单抗类药物治疗,可改善患者的血清CA125、EGFR、CEA指标表达水平,推荐在临床推广运用。
Objective To explore the clinical study of molecular targeted monoclonal antibody drug in the treatment of advanced non-small cell lung cancer on serum CA125 and EGFR levels. Methods 60 patients with advanced non-small cell lung cancer were randomly divided into the control group and the research group,there were 37 cases in each group. The control group was treated with conventional chemotherapy,the treatment group was treated with molecular targeted monoclonal antibody drug on base of chemotherapy. The clinical therapeutic efficacy,the change of advanced non-small cell lung cancer on Serum CA125,EGFR and CEA expression levels and incidence of adverse reactions of the 2 groups were compared. Results The clinical effective rate of the research group and the control group was 56. 67% and 26. 67%,respectively( P < 0. 05);Serum CA125 of the research group and the control group was( 421. 5 ± 73. 8) and( 521. 6 ± 105. 1),serum EGFR of research group and control group was( 40. 5 ± 10. 2) and( 58. 1 ± 13. 5),serum CEA of the research group and the control group was( 3. 2 ± 1. 3) and( 4. 2 ±0. 8),respectively( P < 0. 05);Incidence of adverse reactions of the research group and the control group was 16. 67% and20. 00%,respectively( P > 0. 05). Conclusion Molecular targeted monoclonal antibody drug in the treatment of advanced nonsmall cell lung cancer,can improve the serum CA125,EGFR and CEA expression levels,and is worth popularizing in clinical practice.
作者
詹彩梅
梁冬红
ZHAN Caimei;LIANG Donghong(The Third Affiliated Hospital of Guangdong Medical University,Foshan,528318)
出处
《实用癌症杂志》
2019年第10期1632-1634,共3页
The Practical Journal of Cancer
基金
2017年广东省佛山市自筹经费类科技计划项目(编号:2017125-275)
